
Immuron Limited – NASDAQ:IMRN
Immuron Limited stock price today
Immuron Limited stock price monthly change
Immuron Limited stock price quarterly change
Immuron Limited stock price yearly change
Immuron Limited key metrics
Market Cap | 11.17M |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -0.01 |
Revenue | 2.09M |
EBITDA | -2.05M |
Income | -3.23M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | -98.14% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeImmuron Limited stock price history
Immuron Limited stock forecast
Immuron Limited financial statements
Jun 2023 | 1.22M | -1.80M | -148.08% |
---|
Sep 2022 | 23100805 | 1.83M | 7.95% |
---|---|---|---|
Dec 2022 | 23100805 | 1.83M | 7.95% |
Mar 2023 | 21988182 | 2.37M | 10.78% |
Jun 2023 | 21988182 | 2.37M | 10.78% |
Jun 2017 | -2.40M | -1.90K | 2.83M |
---|---|---|---|
Jun 2022 | -410.31K | 2.07K | -10.74K |
Mar 2023 | -801.58K | -8.85K | -11.58K |
Jun 2023 | -1.54M | -79.96K | -18.02K |
Immuron Limited alternative data
Aug 2023 | 5 |
---|---|
Sep 2023 | 5 |
Oct 2023 | 5 |
Nov 2023 | 6 |
Dec 2023 | 6 |
Jan 2024 | 6 |
Feb 2024 | 6 |
Mar 2024 | 6 |
Apr 2024 | 6 |
May 2024 | 6 |
Jun 2024 | 6 |
Jul 2024 | 6 |
Immuron Limited other data
Quarter | Transcript |
---|---|
Q4 2022 6 Sep 2022 | Q4 2022 Earnings Call Transcript |
-
What's the price of Immuron Limited stock today?
One share of Immuron Limited stock can currently be purchased for approximately $1.81.
-
When is Immuron Limited's next earnings date?
Unfortunately, Immuron Limited's (IMRN) next earnings date is currently unknown.
-
Does Immuron Limited pay dividends?
No, Immuron Limited does not pay dividends.
-
How much money does Immuron Limited make?
Immuron Limited has a market capitalization of 11.17M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 171.67% to 4.9M US dollars.
-
What is Immuron Limited's stock symbol?
Immuron Limited is traded on the NASDAQ under the ticker symbol "IMRN".
-
What is Immuron Limited's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Immuron Limited?
Shares of Immuron Limited can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Immuron Limited have?
As Jul 2024, Immuron Limited employs 6 workers.
-
When Immuron Limited went public?
Immuron Limited is publicly traded company for more then 8 years since IPO on 9 Jun 2017.
-
What is Immuron Limited's official website?
The official website for Immuron Limited is immuron.com.au.
-
Where are Immuron Limited's headquarters?
Immuron Limited is headquartered at 25-37 Chapman Street, Carlton, VIC.
-
How can i contact Immuron Limited?
Immuron Limited's mailing address is 25-37 Chapman Street, Carlton, VIC and company can be reached via phone at +61 3 9824 5254.
Immuron Limited company profile:

Immuron Limited
immuron.com.auNASDAQ
7
Biotechnology
Healthcare
Immuron Limited, a biopharmaceutical company, researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It markets Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and reduce the symptoms of minor gastro-intestinal disorders, as well as for dietary supplement for digestive tract protection; and Protectyn, an immune supplement to maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III clinical trials to reduce the risk of contracting travelers' diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in clinical development stage focuses on treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and ETEC infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is based in Carlton, Australia.
Carlton, VIC 3130
CIK: 0001660046
ISIN: US45254U1016
CUSIP: 45254U101